🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In the 6th #12paperstoChristmas series, we reported a #RCT investigating the effects of expectancy versus actual #gluten intake on symptoms in people with non- #coeliac #glutensensitivity in The Lancet Gastroenterology & Hepatology. Full paper available from: thelancet.com/journals/langa…

Our results necessitate further research into the possible involvement of the #gut–#brain #interaction in #non-#coeliac #gluten #sensitivity

When data for global #IBS symptoms were pooled, drugs (both #ebastine and #ketotifen) acting on #histamine 1 receptors were significantly more effective than placebo.

Mais Khasawneh Chris Black Alexander Ford

Our data indicate that the FADS Indel at #rs66698963 is a key functional polymorphism that predicts n–3 HUFA efficacy for colorectal polyp risk reduction in a randomized trial of EPA

mark hull

In the 10th #12paperstoChristmas series, we reviewed #postprandial symptoms in #DGBI and their potential as a #treatment target in Gut Journal. Full paper available from: gut.bmj.com/content/73/7/1…

We presented #hypothetical mechanisms of #postprandial symptoms in #IBS and #FD.

In the 11th #12paperstoChristmas series, we evaluated the appropriateness of novel small molecules #tofacitinib, #filgotinib, #upadacitinib and #ozanimod (#TFUO) in #women of #childbearing age with #IBD in Therapeutic Advances in Gastroenterology. Full paper available from: journals.sagepub.com/doi/10.1177/17…

#TFUO are contraindicated during #pregnancy and #breastfeeding.

Women receiving #TFUO should cease therapy in time to establish clinical remission for at least 3 months prior to #conception.

Therapies other than #TFUO should be considered as first-line therapy in women with IBD of childbearing age. TFUO may be appropriate for women of childbearing age after failure of, intolerance or contraindications to one biological agent.

In the 12th and final #12paperstoChristmas series, we discussed the #personalisation of therapy in #IBS in The Lancet Gastroenterology & Hepatology. Full paper available from: thelancet.com/journals/langa…

The conventional subtyping of Rome IV #IBS is probably an oversimplification of a complex and multidimensional condition.

We have previously derived a novel classification system for #IBS using latent class analysis #LCA

We have also previously shown that this novel subgrouping of Rome IV #IBS can be used to predict the #prognosis of IBS (symptom severity), health-care use (consultation behaviour, prescribing, and costs), and #impact (QoL, work and productivity, ADLs, and income).

The following approaches for first-line and second-line treatment could be considered according to these subgroups

🎉 Happy New Year from all at FG! Kick off your 2025 with a resolution to keep up to date with all our #onlinefirst content at fg.bmj.com/content/early/… Phil Smith Gio McGinty Vivek Goodoory Philip Dunne Rex Wan-Hin Hui Oliver Tavabie Aditi Kumar

Huge thank you to our departing Frontline Gastro trainee editors 2023-2025. Vivek, Philip, Rex, Gio, James and Mohsen have been fantastic representatives of the journal and Phil Smith Mark Beattie and the whole #FGTeam are very grateful for all their hard work and efforts.

Very grateful to all our departing Frontline Gastro trainee editors 2023-2025 - thank you so much for your hard work and efforts! We will keep in touch and thank you in advance for supporting the new trainee editors! Vivek Goodoory Rex Wan-Hin Hui James Kennedy Gio McGinty Mohsen Subhani